PIPE-Line Gamble Could Let Cadence Sing A Happy Tune
This article was originally published in The Pink Sheet Daily
Executive Summary
Company aims to file NDAs for pain product and topic anti-infective gel in second quarter.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2009
Highlights from the Q1 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $692 million--a 31% drop from Q1 2008 but a 25% increase from last quarter--with most of the money, $544 million, coming from the biopharma sector. There were no significant acquisitions of biopharma or in vitro diagnostic start-up companies in the first quarter of the year, but device giant Medtronic paid a total of $550 million for two start-ups. Cancer was the most popular therapeutic area for start-up alliances this quarter.
Affymax Swings $42 Million Financing To Push Hematide
Private/public infusion will see synthetic ESA through trials and approval.
Sign Of The Times? Micromet’s Stock Price Sluggish Despite Reasons For Optimism
Biotech well-funded thanks to recent deals and sees blockbuster potential in lymphoma with blinatumomab.